Workflow
SaiLong(002898)
icon
Search documents
赛隆药业(002898) - 2024年度董事会工作报告
2025-04-24 13:54
二、董事会日常工作情况 公司董事会共有董事9名,全体董事恪尽职守、勤勉尽责,实时关注公司经 营管理信息、财务状况、重大事项等,对提交董事会审议的各项议案,深入讨 论,为公司的经营发展建言献策,做出决策时充分考虑中小股东的利益和诉 求,切实增强了董事会决策的科学性,推动公司生产经营各项工作的持续、稳 定、健康发展。 (一)董事会会议召开情况 2024 年度,公司董事会共召开了 7 次董事会会议。所有会议的召集、召开 程序均符合《公司法》、《公司章程》和《董事会议事规则》的有关规定,会 议合法有效。董事会会议召开的具体情况如下: 1.第三届董事会第十七次会议 赛隆药业集团股份有限公司 2024 年度董事会工作报告 2024 年,赛隆药业集团股份有限公司(以下简称"公司")全体董事严格 遵守《公司法》、《证券法》、《深圳证券交易所股票上市规则》等法律、法 规及《公司章程》、《董事会议事规则》的相关规定,切实履行各项职责,积 极有效地开展董事会各项工作,严格执行股东大会各项决议,维护公司和全体 股东的合法权益,保障公司规范运作和长远发展。现将 2024 年度董事会工作报 告如下: 一、2024 年公司总体经营情况 2 ...
赛隆药业:4月28日起被实施退市风险警示 股票简称变更为“*ST赛隆”
news flash· 2025-04-24 13:47
智通财经4月24日电,赛隆药业(002898.SZ)公告称,公司2024年度利润总额、净利润、扣除非经常性损 益后的净利润三者均为负值,且扣除后的营业收入低于3亿元。根据相关规定,公司股票交易将被深圳 证券交易所实施退市风险警示。公司股票于4月25日(星期五)开市起停牌一天,并于4月28日(星期 一)开市起复牌。公司股票自4月28日开市起被实施"退市风险警示",股票简称由"赛隆药业"变更 为"*ST赛隆",证券代码仍为"002898"。实施退市风险警示后公司股票交易的日涨跌幅限制为5%。 赛隆药业:4月28日起被实施退市风险警示 股票简称变更为"*ST赛隆" ...
赛隆药业(002898) - 年度股东大会通知
2025-04-24 13:46
证券代码:002898 证券简称:赛隆药业 公告编号:2025-019 赛隆药业集团股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司(以下简称"公司")于 2025 年 4 月 23 日召开 第四届董事会第八次会议,审议通过了《关于召开 2024 年度股东大会的议案》, 公司决定于 2025 年 5 月 16 日在珠海市香洲区南湾北路 31 号 2 单元 21 层公司 会议室采取现场会议与网络投票相结合的方式召开 2024 年度股东大会,现将有 关事项通知如下: 一、召开会议的基本情况 1. 股东大会届次:2024 年度股东大会。 2.股东大会的召集人:公司董事会。 3.会议召开的合法、合规性:本次股东大会的召开已经公司第四届董事会 第八次会议审议通过,符合公司法、《公司章程》等相关规定。 4.会议召开的日期、时间: (1)现场会议:2025 年 5 月 16 日(星期五)15:00 (2)网络投票时间:通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 16 ...
赛隆药业(002898) - 2024 Q4 - 年度财报
2025-04-24 13:45
Financial Performance - The company's operating revenue for 2024 was CNY 263,567,276.85, a decrease of 15.15% compared to CNY 310,627,026.68 in 2023[16]. - The net profit attributable to shareholders for 2024 was a loss of CNY 33,145,611.22, representing a decline of 447.67% from a profit of CNY 9,533,684.57 in 2023[16]. - The cash flow from operating activities for 2024 was a negative CNY 38,861,029.43, a decrease of 208.83% compared to CNY 35,706,967.41 in 2023[16]. - The basic earnings per share for 2024 was -0.1883, down 447.42% from 0.0542 in 2023[16]. - Total assets at the end of 2024 were CNY 808,223,377.29, a decrease of 0.69% from CNY 813,843,574.35 at the end of 2023[16]. - The net assets attributable to shareholders at the end of 2024 were CNY 499,277,281.69, down 6.83% from CNY 535,881,684.91 at the end of 2023[16]. - The company reported a significant increase in non-recurring losses, with the net profit excluding non-recurring items at -CNY 33,499,631.23 for 2024[16]. - The weighted average return on equity for 2024 was -6.40%, down from 1.80% in 2023[16]. Market and Industry Context - The pharmaceutical manufacturing industry in China reported a total revenue of 25,298.5 billion yuan in 2024, remaining flat compared to the previous year, with a profit total of 3,420.7 billion yuan, down 1.1% year-on-year[26]. - The company is positioned in the pharmaceutical manufacturing industry, which is undergoing significant reforms and challenges, including price reductions and increased competition due to centralized procurement policies[26][27]. - The company is focused on expanding its market presence and enhancing product quality in response to the evolving regulatory landscape and industry standards[28][29]. Research and Development - The company continues to invest in R&D for its main products, including injectable drugs and active pharmaceutical ingredients, maintaining its commitment to technological advancement in the pharmaceutical sector[30]. - The company employs a research and development model primarily focused on independent R&D, supported by collaborative development[33]. - The company has established a pharmaceutical R&D center with a team experienced in innovation and development[33]. - The company has received approval notifications for 21 types of active pharmaceutical ingredients (APIs) and 13 formulations, demonstrating its ongoing commitment to R&D innovation[35]. - The company is actively involved in new drug development based on market demand and existing product advantages[33]. Financial Management and Governance - The company has established a robust internal audit system to monitor and evaluate internal control activities, effectively managing risks[90]. - The company has independent financial accounting departments and maintains independent bank accounts, ensuring financial independence from the controlling shareholder[95]. - The company has established a clear governance structure, ensuring independence in business, assets, personnel, and finance from the controlling shareholder[92]. - The company has a designated board secretary responsible for investor relations and information disclosure, ensuring transparency[89]. - The company has a structured remuneration decision-making process involving the board's remuneration and assessment committee[114]. Environmental Compliance - The company has implemented measures to ensure compliance with environmental regulations during production, with plans for increased investment in digital environmental monitoring[76]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a documented emergency plan and regular employee drills[145]. - The company prioritizes environmental considerations in production processes and pollution prevention technologies, utilizing advanced disposal techniques and equipment that meet national standards[143]. Employee and Management Changes - The company experienced a change in management with the appointment of Cai Nangu as President on April 3, 2024[103]. - Long Zhixiang resigned from his position as Supervisor and Chairman of the Supervisory Board due to personal reasons on October 11, 2024[103]. - The company is focused on maintaining stability during the management transition period[103]. Shareholder and Capital Structure - The company has a total of 176,000,000 shares as the basis for its distribution plan, with no dividends proposed[130]. - The total number of shares before the change was 176,000,000, which remained unchanged after the adjustment[190]. - The number of shareholders holding ordinary shares at the end of the reporting period was 16,227, a decrease from 17,462 at the end of the previous month[191]. Future Outlook - The company plans to expand its market presence and invest in new product development, aiming for a growth rate of 15% in the next fiscal year[194]. - Future outlook remains positive, with expectations of continued growth driven by innovation and market expansion strategies[110].
赛隆药业(002898) - 2025 Q1 - 季度财报
2025-04-24 13:45
Financial Performance - The company's revenue for Q1 2025 was ¥54,086,779.12, a decrease of 22.16% compared to ¥69,484,400.80 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,038,505.28, representing a decline of 163.94% from a profit of ¥1,624,090.66 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0059, down 164.13% from ¥0.0092 in the previous year[5] - The net profit for the current period is -1,038,505.28, compared to a net profit of 1,624,090.66 in the previous period, indicating a significant decline[18] - Operating profit for the current period is -1,073,070.53, down from 2,177,192.65 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities improved by 26.09%, with a net outflow of ¥12,886,962.58 compared to ¥17,436,292.79 in the same period last year[5] - The company recorded a net cash outflow from investing activities of ¥1,990,177.26, a decline of 267.66% compared to a net inflow of ¥1,187,045.07 in the previous year[8] - The cash and cash equivalents have decreased to ¥32,973,514.85 from ¥48,843,383.16, representing a decline of approximately 32.5%[13] - Cash and cash equivalents at the end of the period decreased to 32,097,514.85 from 54,532,212.02 in the previous period[20] - The company received cash inflow from financing activities of 36,700,000.00, compared to 20,000,000.00 in the previous period, indicating increased borrowing[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥806,068,851.46, a slight decrease of 0.27% from ¥808,223,377.29 at the end of the previous year[5] - The total current assets have increased slightly to ¥251,821,316.13 from ¥249,830,978.43, showing a growth of about 0.8%[14] - The total liabilities have decreased to ¥307,548,596.99 from ¥308,946,095.60, reflecting a decline of approximately 0.5%[15] - The total assets amount to ¥806,068,851.46, which is a slight decrease from ¥808,223,377.29, indicating a reduction of about 0.3%[15] Expenses - The company's sales expenses increased by 70.74% to ¥9,311,231.72, attributed to increased sales activities during the period[8] - Research and development expenses increased to 6,059,564.36 from 5,344,923.89, reflecting a focus on innovation[18] - The company incurred a financial expense of 1,721,374.90, up from 1,460,757.48, primarily due to interest expenses[18] Accounts Receivable and Inventory - The accounts receivable have increased to ¥84,401,321.66 from ¥67,046,975.03, marking an increase of about 25.9%[13] - The inventory has decreased to ¥89,391,143.96 from ¥94,077,645.27, indicating a reduction of approximately 5.0%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,462, with the largest shareholder holding 51.15% of the shares[10]
赛隆药业(002898) - 监事会决议公告
2025-04-24 13:45
赛隆药业集团股份有限公司 第四届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 证券代码:002898 证券简称:赛隆药业 公告编号:2025-015 赛隆药业集团股份有限公司(以下简称"公司")第四届监事会第八次会议 通知于 2025 年 4 月 13 日以专人送达、电子邮件、电话相结合的方式送达各位监 事。会议于 2025 年 4 月 23 日在湖南省长沙市长沙县星沙产业基地红枫路 1 号湖 南赛隆药业(长沙)有限公司会议室以现场和通讯相结合的方式召开,本次会议 应出席监事 3 人,实际出席监事 3 人。会议由监事会主席周蓓女士召集和主持。 本次会议的召集、召开程序符合《公司法》等有关法律、法规、规范性文件及《公 司章程》的规定。 二、监事会会议审议情况 1.审议并通过了《关于 2024 年度监事会工作报告的议案》 具体内容详见同日刊登于巨潮资讯网(www.cninfo.com.cn)上的《2024 年 度监事会工作报告》。 表决结果:表决票 3 票,赞成票 3 票,反对票 0 票,弃权票 0 票。 本项议 ...
赛隆药业(002898) - 董事会决议公告
2025-04-24 13:43
证券代码:002898 证券简称:赛隆药业 公告编号:2025-014 赛隆药业集团股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 赛隆药业集团股份有限公司(以下简称"公司")第四届董事会第八次会议 通知于 2025 年 4 月 13 日以书面方式通过专人送出、传真、电子邮件相结合的方 式送达各位董事。会议于 2025 年 4 月 23 日在珠海市香洲区南湾北路 31 号 2 单 元 21 层公司会议室以现场及通讯相结合的方式召开,会议应到董事 9 人,实际 出席董事 9 人,会议由公司董事长蔡南桂先生主持,公司监事和高级管理人员列 席本次会议。本次会议的召集、召开和表决符合有关法律、行政法规、其他规范 性文件和《公司章程》的规定。 二、董事会会议审议情况 1.审议并通过了《关于 2024 年度总裁工作报告的议案》 表决结果:表决票数 9 票,赞成 9 票,反对 0 票,弃权 0 票。 2.审议并通过了《关于 2024 年度董事会工作报告的议案》 具体内容详见同日刊登在巨潮资讯网(www.c ...
赛隆药业:2024年净亏损3314.56万元
news flash· 2025-04-24 13:43
赛隆药业(002898)公告,2024年营业收入2.64亿元,同比下降15.15%。归属于上市公司股东的净亏损 3314.56万元,去年同期净利润953.37万元。基本每股收益-0.1883元/股。公司董事会审议通过的利润分 配预案为不派发现金红利,不送红股,不以资本公积金转增股本。 ...
赛隆药业(002898) - 关于2024年度拟不进行利润分配的专项说明
2025-04-24 13:42
证券代码:002898 证券简称:赛隆药业 公告编号:2025-018 赛隆药业集团股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 | 项目 | 本年度 | 上年度 | 上上年度 | | --- | --- | --- | --- | | 现金分红总额(元) | 0 | 3,520,000.00 | 0 | | 回购注销总额(元) | 0 | 0 | 0 | | 归属于上市公司股东的 | -33,145,611.22 | 9,533,684.57 | -37,312,314.25 | | 净利润(元) | | | | | 合并报表本年度末累计 | | 16,736,952.88 | | | 未分配利润(元) | | | | | 母公司报表本年度末累 | | -7,458,139.13 | | | 计未分配利润(元) | | | | | 上市是否满三个 | | 是 | | | 完整会计年度 | | | | | 最近三个会计年度累计 | | 3,520,000.00 | | | 现金分红总额(元) | ...
赛隆药业(002898) - 关于公司股票交易被实施退市风险警示暨停牌的公告
2025-04-24 13:42
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 1.赛隆药业集团股份有限公司(以下简称"公司")于 2025 年 4 月 25 日在 巨潮资讯网(www.cninfo.com.cn)披露了《2024 年年度报告》,经审计的年度 报告数据显示,公司 2024 年度利润总额、净利润、扣除非经常性损益后的净利 润三者均为负值,且扣除后的营业收入低于 3 亿元。根据《深圳证券交易所股票 上市规则》第 9.3.1 条规定,公司股票交易将被深圳证券交易所实施退市风险警 示。 证券代码:002898 证券简称:赛隆药业 公告编号:2025-020 赛隆药业集团股份有限公司 关于公司股票交易被实施退市风险警示暨停牌的 公告 2.公司股票于 2025 年 4 月 25 日(星期五)开市起停牌一天,并于 2025 年 4 月 28 日(星期一)开市起复牌。 3.公司股票自 2025 年 4 月 28 日开市起被实施"退市风险警示",股票简称 由"赛隆药业"变更为"*ST 赛隆",证券代码仍为"002898"。实施退市风险 警示后公司股票交易的日涨跌幅限制为 5%。 一 ...